31 General introduction 1 47. Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet 2021;397:1505-1518. 48. Saengjaroentham C, Strother LC, Dripps I, et al. Differential medication overuse risk of novel anti-migraine therapeutics. Brain 2020;143:2681-2688. 49. Rau JC, Navratilova E, Oyarzo J, et al. Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache. Cephalalgia 2020;40:903-912. 50. Navratilova E, Behravesh S, Oyarzo J, Dodick DW, Banerjee P, Porreca F. Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia 2020;40:892-902. 51. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, doubleblind, placebo-controlled trial. Lancet 2019;394:737-745. 52. Rubio-Beltrán E, Schoon RM, van den Berg J, et al. Trigeminovascular effects of propranolol in men and women, role for sex steroids. Annals of Clinical and Translational Neurology 2022;9:1405-1416. 53. Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997;17:109-112. 54. Porreca F, Navratilova E, Hirman J, van den Brink AM, Lipton RB, Dodick DW. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia 2024;44:3331024241238153. 55. Wyon YAM, Spetz A-CE, Theodorsson GE, Hammar ML. Concentrations of Calcitonin GeneRelated Peptide and Neuropeptide Y in Plasma Increase During Flushes in Postmenopausal Women. Menopause 2000;7. 56. Wilhelms DB, Dock H, Brito HO, et al. CGRP Is Critical for Hot Flushes in Ovariectomized Mice. Frontiers in Pharmacology 2019;9. 57. Coffee AL, Sulak PJ, Hill AJ, Hansen DJ, Kuehl TJ, Clark JW. Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines. J Womens Health (Larchmt) 2014;23:310-317. 58. Calhoun AH. A novel specific prophylaxis for menstrual-associated migraine. South Med J 2004;97:819-822. 59. Nappi RE, Terreno E, Sances G, et al. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception 2013;88:369-375. 60. Morotti M, Remorgida V, Venturini PL, Ferrero S. Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study. Eur J Obstet Gynecol Reprod Biol 2014;183:178-182. 61. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology 2006;67:21592163.
RkJQdWJsaXNoZXIy MjY0ODMw